Articles tagged "Induction therapy"

2019 American Transplant Congress
Rabbit Anti-Thymocyte Globulin (rATG) Induction in Heart Transplant Recipients at High Risk for Rejection
B. Kitto¹, B. Baetz¹, S. Krim², H. Patel², S. Mandras², S. Desai², C. Eiswirth², H. Ventura², S. Thai¹
¹Pharmacy, Ochsner Medical Center, New Orleans, LA, ²Heart Transplant, Ochsner Medical Center, New Orleans, LA
*Purpose: To assess the safety and efficacy of rATG induction in heart transplant recipients at high risk for rejection.*Methods: This was a single-center, retrospective study…
2019 American Transplant Congress
Outcomes Of Dosing Weight Selection On Rabbit Anti-thymocyte Globulin Induction Immunosuppression In High-risk, Obese Renal Transplant Recipients
A. C. Cordry¹, K. Trobaugh¹, L. Ramsey², A. L. Castellanos³, H. Fattah³, T. Rendulic¹
¹Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²University of Kentucky College of Pharmacy, Lexington, KY, ³Nephrology, University of Kentucky HealthCare, Lexington, KY
*Purpose: There are limited data regarding the optimal weight-based dosing strategy for rabbit anti-thymocyte globulin (rATG) induction in renal transplantation. At our center, rATG is…
2019 American Transplant Congress
Antithymocyte Globulin is Associated with Mature T Cell Phenotypes and Decreased Risk of Non-EBV Infections in Transplanted Children
B. I. Shaw¹, L. Stempora¹, C. Chan¹, R. B. Ettenger², P. C. Grimm³, H. Lee¹, E. F. Reed², M. M. Sarwal⁴, B. L. Warshaw⁵, C. Zhao¹, O. M. Martinez³, A. D. Kirk¹, E. T. Chambers¹
¹Pediatrics/Surgery, Duke University, Durham, NC, ²Pediatrics, University of California, Los Angeles, Los Angeles, CA, ³Pediatrics/Surgery, Stanford University, Palo Alto, CA, ⁴Pediatrics/Surgery, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Emory University, Atlanta, GA
*Purpose: Depletional induction therapies are known to reduce the rate of acute rejection; yet data from the US Renal Data System have shown that use…
2019 American Transplant Congress
Induction Therapy in Elderly Kidney Transplant Recipients with Low Immunological Risk
C. Masset¹, J. Boucquemont², V. Garrigue³, M. Ladrière⁴, F. Buron⁵, E. Cassuto⁶, Y. Foucher², J. Dantal¹
¹University Hospital of Nantes, Nantes, France, ²University of Nantes, Nantes, France, ³University Hospital of Montpellier, Montpellier, France, ⁴University Hospital of Nancy, Nancy, France, ⁵University Hospital of Lyon, Lyon, France, ⁶University Hospital of Nice, Nice, France
*Purpose: Thymoglobulin (ATG) and Basiliximab (BSX) lead to similar rejection rates in low immunological risk patients. ATG seems to be associated with infectious and malignancy…
2019 American Transplant Congress
Outcomes of Induction Therapy with Bortezomib and High-Dose Intravenous Immunoglobulin for Kidney Transplantation with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika
Department of Urology, Ehime University, Toon, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are known to increase the risk of antibody-mediated rejection (ABMR) and graft failure. However, effective methods…
2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
J. Lei¹, H. Deng¹, K. Lee¹, C. Peters¹, G. Rickert¹, R. Ivy¹, M. Coronel², E. Yolcu³, H. Shirwan⁴, A. García⁵, J. Markmann¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Surgery, Georgia Institute of Technology, Atlanta, GA, ³Institute for Cellular Therapeutics, University of Louisville School of Medicine, louisville, KY, ⁴Department of Microbiology and Immunology, University of Louisville School of Medicine, louisville, KY, ⁵School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…
2019 American Transplant Congress
Safety and Efficacy of Alemtuzumab Compared to Rabbit Anti-Thymocyte Globulin as Induction for Secondary Transplant after a Primary Transplant with Alemtuzumab Induction
J. L. Fose¹, M. R. Jorgenson¹, G. E. Leverson², R. R. Redfield²
¹Pharmacy, UW Health, Madison, WI, ²University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI
*Purpose: Alemtuzumab and rabbit anti-thymocyte globulin (rATG) are commonly used lymphocyte depleting induction agents. Traditional thinking suggests that re-transplantation is associated with higher rejection risk,…
2019 American Transplant Congress
Panel Reactive Antibody Stratification as a Guide to Induction Selection in Deceased-Donor Kidney Transplantation: Impact of Clinical Practice on Outcomes
H. Ibrahim¹, J. Gregg¹, K. Alquadan¹, U. Akanit², K. L. Womer¹, A. H. Santos¹
¹Medicine, University of Florida, Gainesville, FL, ²Ubon Ratchathani University, Ubonratchathani, Thailand
*Purpose: We aimed to determine the outcomes associated with anti-thymocyte globulin (ATG), alemtuzumab (ALM) or interleukin-2 receptor antagonist (IL2-RA) induction in adult deceased-donor (DD) kidney…
2019 American Transplant Congress
Simultaneous Pancreas and Kidney Transplant Outcomes after Induction Therapy with Thymoglobulin Compared with Alemtuzumab
B. Masters¹, F. Bartlett², C. Drachenberg³, S. Bartlett³, R. Barth³, J. Scalea³, A. Haririan³
¹University of Maryland Medical Center, Baltimore, MD, ²Barnes-Jewish Hospital, St. Louis, MO, ³University of Maryland, School of Medicine, Baltimore, MD
*Purpose: The purpose of this study is to compare the outcomes of simultaneous pancreas and kidney transplant (SPK) recipients after two T-cell depleting induction agents:…
2019 American Transplant Congress
Alemtuzumab Induction in Living Donor Renal Transplantation
O. Witkowsky, H. Winters, K. Washburn, G. Bumgardner, A. Rajab, A. El-Hinnawi, T. Pesavento
The Ohio State University Wexner Medical center, Columbus, OH
*Purpose: About 15% of kidney transplant (KT) recipients receive alemtuzumab (ALM) for induction. The aim of this study was to review outcomes in living donor…